Baxter and Merrimack enter exclusive licensing agreement for MM-398 compound outside the USA

24 September 2014

Baxter International (NYSE: BAX) and oncology specialist Merrimack (Nasdaq: MACK) have launched a collaboration to develop and commercialize MM-398 (nanoliposomal irinotecan injection).

Baxter will gain exclusive commercialization rights for all potential indications of MM-398 outside the USA and Taiwan, and Merrimack will be able to commercialize in the USA. The Taiwanese rights are held separately.

It is an investigational candidate for which Merrimack is preparing a New Drug Application for the US Food and Drug Administration for the treatment of metastastic pancreatic cancer previously treated with a gemcitabine-based therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK